Professor Peter Hoffmann is President of the Australasian Proteomics Society, Conference Chair for the National Meeting of the Australasian Proteomics Society, and is Treasurer of the international Human Proteome Organisation (HUPO). For ten years, Peter’s research has delved into the identification of low abundant proteins and the mapping of their posttranslational modifications and their use as potential biomarkers for early detection of diseases, one of the biggest challenges in proteomics. He is leader in the field of Mass Spectrometry Imaging and his research group was the first to use this technology in Australia. He is Director of the NCRIS Bioplatforms Astralia Node for Tissue Imaging Mass Spectrometry. He has... Read more
About me
Professor Peter Hoffmann is President of the Australasian Proteomics Society, Conference Chair for the National Meeting of the Australasian Proteomics Society, and is Treasurer of the international Human Proteome Organisation (HUPO). For ten years, Peter’s research has delved into the identification of low abundant proteins and the mapping of their posttranslational modifications and their use as potential biomarkers for early detection of diseases, one of the biggest challenges in proteomics. He is leader in the field of Mass Spectrometry Imaging and his research group was the first to use this technology in Australia. He is Director of the NCRIS Bioplatforms Astralia Node for Tissue Imaging Mass Spectrometry. He has experience transforming research into industry-relevant outcomes, forming Onco DX to commercialise patented biomarkers for the early detection of ovarian and gastric cancer.
Research
Excludes commercial-in-confidence projects.
Assessment of current best practice techniques for handling pesticides in forestry applications, Forest and Wood Products Australia, 15/06/2023 - 31/03/2026
Nanoparticle regulation of DNA replication and repair pathways, ARC - Discovery Projects, 21/01/2019 - 29/06/2023
Enabling personalised medicine for patients with ovarian cancer, Tour de Cure Ltd, 01/11/2021 - 31/12/2022
Ovarian Blood Markers of Ovarian Cancer (phase 1 transfer in), Ovarian Cancer Research Foundation Inc, 04/12/2017 - 30/06/2018
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2021 |
1
|
2019 |
2
1
|
2017 |
49
36
1
|
Year | Output |
---|---|
2024 |
Open access
|
2024 |
Open access
|
2023 |
Open access
|
2023 |
Open access
|
2023 |
Open access
|
2023 |
Open access
|
2023 |
|
2023 |
|
2023 |
Open access
|
2023 |
Open access
3
4
|
2022 |
Open access
1
1
2
|
2022 |
Open access
1
1
|
2022 |
Open access
9
7
8
|
2022 |
Open access
2
1
|
2022 |
Open access
2
1
|
2022 |
Open access
3
1
5
|
2022 |
Open access
2
1
2
|
2022 |
1
1
1
|
2021 |
20
1
|
2021 |
Open access
10
4
|
2021 |
Open access
6
2
1
|
2021 |
10
6
3
|
2021 |
Open access
4
4
1
|
2021 |
Open access
14
13
1
|
2021 |
9
7
1
|
2020 |
Open access
4
3
|
2020 |
Open access
10
10
8
|
2020 |
Open access
8
7
64
|
2020 |
Open access
9
7
4
|
2020 |
Open access
5
3
2
|
2019 |
Open access
40
34
8
|
2019 |
Open access
14
8
2
|
2019 |
Open access
41
43
17
|
2019 |
Open access
45
38
16
|
2019 |
10
10
6
|
2019 |
2
1
9
|
2019 |
Open access
8
6
3
|
2019 |
Open access
8
8
|
2019 |
Open access
12
10
3
|
2018 |
Open access
17
13
1
|
2018 |
Open access
3
3
3
|
2018 |
Open access
13
9
17
|
2018 |
16
12
2
|
2018 |
Open access
14
11
38
|
2017 |
Open access
24
19
2
|
2017 |
Open access
3
3
|
2017 |
21
20
1
|
2017 |
1
1
2
|
2017 |
Open access
36
32
|
2017 |
Open access
9
8
|
2016 |
Open access
40
35
5
|
2016 |
Open access
11
12
1
|
2016 |
Open access
92
88
10
|
2016 |
Open access
25
23
|
2016 |
Open access
23
21
11
|
2016 |
Open access
20
18
10
|
2016 |
Open access
35
31
|
2016 |
Open access
32
28
12
|
2016 |
Open access
26
25
2
|
2016 |
Open access
6
6
4
|
2016 |
Open access
9
9
2
|
2016 |
Open access
28
27
1
|
2016 |
Open access
12
9
7
|
2015 |
Open access
19
17
1
|
2015 |
84
62
10
|
2015 |
Open access
|
2015 |
Open access
34
30
1
|
2015 |
Open access
87
80
17
|
2015 |
Open access
33
71
9
|
2015 |
Open access
80
76
|
2015 |
48
44
1
|
2015 |
7
7
10
|
2015 |
Open access
11
10
3
|
2014 |
Open access
38
37
64
|
2014 |
45
41
31
|
2014 |
Open access
12
11
|
2014 |
Open access
1
|
2014 |
9
9
1
|
2014 |
13
12
1
|
2013 |
22
19
|
2013 |
Open access
57
51
5
|
2013 |
Open access
56
49
|
2013 |
47
1
|
2013 |
Open access
7
3
|
2013 |
Open access
38
36
|
2013 |
44
33
|
2013 |
Open access
46
33
|
2012 |
Open access
|
2012 |
Open access
45
43
|
2012 |
13
11
|
2012 |
|
2012 |
42
42
|
2012 |
|
2012 |
32
25
|
2012 |
27
25
|
2012 |
3
3
|
2012 |
3
|
2012 |
25
24
|
2012 |
Open access
27
23
|
2012 |
Open access
8
|
2012 |
Open access
22
23
|
2012 |
Open access
23
23
|
2011 |
63
60
|
2011 |
9
7
|
2011 |
Open access
80
76
|
2011 |
Open access
7
5
|
2011 |
16
16
|
2011 |
9
8
|
2011 |
Open access
57
55
|
2010 |
7
7
|
2010 |
3
|
2010 |
87
87
|
2010 |
61
53
|
2010 |
Open access
83
76
|
2009 |
12
12
|
2009 |
8
8
|
2009 |
Open access
33
29
|
2009 |
18
17
|
2009 |
26
24
|
2009 |
35
32
|
2009 |
28
26
|
2009 |
4
4
|
2009 |
23
23
|
2008 |
8
10
|
2008 |
Open access
78
69
|
2008 |
Open access
|
2008 |
9
|
2008 |
Open access
3
57
|
Year | Output |
---|---|
2016 |
|
2016 |
2
1
|
2015 |
|
2013 |
|
2012 |
1
|
2011 |
2
|
External engagement & recognition
Organisation | Country |
---|---|
Academia Sinica | TAIWAN |
Agricultural Research Service | UNITED STATES |
Australian Federal Police | AUSTRALIA |
Australian National University | AUSTRALIA |
Australian Nuclear Science and Technology Organisation | AUSTRALIA |
Boehringer Ingelheim Pharma GmbH & Co. KG | GERMANY |
Bruker | AUSTRALIA |
Central Mindanao University | PHILIPPINES |
Chris O'Brien Lifehouse | AUSTRALIA |
Clinpath Pathology | AUSTRALIA |
Coopers Brewery | AUSTRALIA |
Coopers Brewery Limited | AUSTRALIA |
CSIRO Australia (Commonwealth Scientific Industrial Research Organisation) | AUSTRALIA |
CSL Limited | AUSTRALIA |
Curtin University | AUSTRALIA |
Flinders University | AUSTRALIA |
Forensic Science SA | AUSTRALIA |
GE Healthcare | UNITED STATES |
Griffith University | AUSTRALIA |
Hudson Institute of Medical Research | AUSTRALIA |
Institute of Medical and Veterinary Science | AUSTRALIA |
Kyoto University | JAPAN |
La Trobe University | AUSTRALIA |
Ludwig Institute for Cancer Research | AUSTRALIA |
Macquarie University | AUSTRALIA |
Martin-Luther University | GERMANY |
Medical College of Wisconsin | UNITED STATES |
Molecular Genetics | AUSTRALIA |
Monash Health | AUSTRALIA |
Monash Medical Centre | AUSTRALIA |
Monash University | AUSTRALIA |
MSU‐Iligan Institute of Technology | PHILIPPINES |
National University of Malaysia | MALAYSIA |
National University of Singapore | SINGAPORE |
Novartis Institutes for BioMedical Research | UNITED STATES |
Peter MacCallum Cancer Centre | AUSTRALIA |
Proteomics International | AUSTRALIA |
Purdue University | UNITED STATES |
Queen Elizabeth Hospital | AUSTRALIA |
Royal Adelaide Hospital | AUSTRALIA |
Royal Brisbane and Women's Hospital | AUSTRALIA |
Royal Children's Hospital, Victoria | AUSTRALIA |
Royal Prince Alfred Hospital | AUSTRALIA |
SA Pathology | AUSTRALIA |
Sechenov University | RUSSIAN FEDERATION |
Sir Charles Gardiner Hospital | AUSTRALIA |
South Australian Health and Medical Research Institute (SAHMRI) | AUSTRALIA |
St. Vincent's Institute of Medical Research | AUSTRALIA |
Thammasat University | THAILAND |
Tubingen University Hospital | GERMANY |
University of Adelaide | AUSTRALIA |
University Of Arkansas For Medical Sciences | UNITED STATES |
University of Auckland | NEW ZEALAND |
University of California San Diego | UNITED STATES |
University of Cambridge | UNITED KINGDOM |
University of Dundee | UNITED KINGDOM |
University of Düsseldorf | GERMANY |
University of Erlangen-Nuremberg | GERMANY |
University of Glasgow | UNITED KINGDOM |
University of Gothenburg | SWEDEN |
University of Kiel | GERMANY |
University of Leipzig | GERMANY |
University of London | UNITED KINGDOM |
University of Macau | MACAU (SAR OF CHINA) |
University of Manchester | UNITED KINGDOM |
University of Melbourne | AUSTRALIA |
University of New South Wales | AUSTRALIA |
University of North Carolina at Chapel Hill | UNITED STATES |
University of North Texas | UNITED STATES |
University of North Texas Health Science Center | UNITED STATES |
University of Queensland | AUSTRALIA |
University of Rome Tor Vergata | ITALY |
University of Science, Malaysia | MALAYSIA |
University of South Australia | AUSTRALIA |
University of Stuttgart | GERMANY |
University of Sydney | AUSTRALIA |
University of Technology Sydney | AUSTRALIA |
University of Western Australia | AUSTRALIA |
University of Wollongong | AUSTRALIA |
Victorian Health and Human Services Building Authority | AUSTRALIA |
Walter and Eliza Hall Institute of Medical Research | AUSTRALIA |
Western Sydney University | AUSTRALIA |
Women's & Children's Health Research Institute Inc | AUSTRALIA |
Women's and Children's Health Network | AUSTRALIA |
Women's and Children's Hospital | AUSTRALIA |
Yonsei University | KOREA, REPUBLIC OF (SOUTH) |
External engagement & recognition
Engagement/recognition | Year |
---|---|
Executive EditorJournal of Proteomics |
2020 |
Executive EditorJournal of Proteomics |
2019 |
Executive EditorJournal of Proteomics |
2018 |
Council MemberHUPO |
2017 |
Executive EditorJournal of Proteomics |
2017 |
Treasurer and Executive Committee MemberHuman Proteome Organization (HUPO) |
2017 |
Ad-Hoc Grant AssessorNational Health and Medical Research Council (NHMRC) |
2016 |
Ad-Hoc Grant AssessorAustralian Cancer Research Foundation |
2016 |
Ad-Hoc Grant AssessorAustralian Research Council (ARC) |
2016 |
Ad-Hoc Grant AssessorDFG |
2016 |
Ad-Hoc Grant AssessorRoyal Children Hospital Foundation |
2016 |
Council MemberHUPO |
2016 |
Guest EditorBiochimica et Biophysica Acta (BBA) |
2016 |
Invited presentationOURCON IV, Ustron, Poland |
2016 |
Keynote SpeakerHUPO, Taipei, Taiwan |
2016 |
Manuscript ReviewerAnalytical Chemistry |
2016 |
Manuscript ReviewerJournal of Chromatography A |
2016 |
Manuscript ReviewerJournal of Peptide Science |
2016 |
Manuscript ReviewerJournal of Proteome Research |
2016 |
Manuscript ReviewerJournal of Proteomics |
2016 |
Manuscript ReviewerMolecular and Cellular Proteomics |
2016 |
Manuscript ReviewerProteomics |
2016 |
Manuscript ReviewerRapid Communication in Mass Spectrometry |
2016 |
Manuscript ReviewerTalanta |
2016 |
SA representativeAustralasian Peptide Association |
2016 |
Vice PresidentAustralasian Proteomics Society |
2016 |
Vice President and Conference ChairLorne Proteomics Symposium |
2016 |
Ad-Hoc Grant AssessorNational Health and Medical Research Council (NHMRC) |
2015 |
Ad-Hoc Grant AssessorAustralian Cancer Research Foundation |
2015 |
Ad-Hoc Grant AssessorAustralian Research Council (ARC) |
2015 |
Ad-Hoc Grant AssessorDFG |
2015 |
Ad-Hoc Grant AssessorRoyal Children Hospital Foundation |
2015 |
Biochemistry Project Grant Review Panel MemberNational Health and Medical Research Council (NHMRC) |
2015 |
Council MemberHUPO |
2015 |
Invited presentationHUPO, Vancouver, Canada |
2015 |
Invited presentationOURCON III, Pisa, Italy |
2015 |
SA representativeAustralasian Peptide Association |
2015 |
Vice PresidentAustralasian Proteomics Society |
2015 |
Vice President and Conference ChairLorne Proteomics Symposium |
2015 |
Ad-Hoc Grant AssessorNational Health and Medical Research Council (NHMRC) |
2014 |
Ad-Hoc Grant AssessorAustralian Cancer Research Foundation |
2014 |
Ad-Hoc Grant AssessorAustralian Research Council (ARC) |
2014 |
Ad-Hoc Grant AssessorDFG |
2014 |
Ad-Hoc Grant AssessorRoyal Children Hospital Foundation |
2014 |
Invited presentationAnalytica, Munich Germany |
2014 |
Invited presentationOURCON II, Antalya, Turkey |
2014 |
SA representativeAustralasian Peptide Association |
2014 |
Session Chair and Session OrganiserAnalytica Conference Munich |
2014 |
Vice PresidentAustralasian Proteomics Society |
2014 |
Vice President and Conference ChairLorne Proteomics Symposium |
2014 |
Ad-Hoc Grant AssessorNational Health and Medical Research Council (NHMRC) |
2013 |
Ad-Hoc Grant AssessorAustralian Cancer Research Foundation |
2013 |
Ad-Hoc Grant AssessorAustralian Research Council (ARC) |
2013 |
Ad-Hoc Grant AssessorDFG |
2013 |
Ad-Hoc Grant AssessorRoyal Children Hospital Foundation |
2013 |
Invited presentationProteomics Forum, Berlin, Germany |
2013 |
Invited presentationProteomics Forum, Penang Malaysia |
2013 |
SA representativeAustralasian Peptide Association |
2013 |
Vice PresidentAustralasian Proteomics Society |
2013 |
Vice President and Conference ChairLorne Proteomics Symposium |
2013 |
Ad-Hoc Grant AssessorNational Health and Medical Research Council (NHMRC) |
2012 |
Ad-Hoc Grant AssessorAustralian Cancer Research Foundation |
2012 |
Ad-Hoc Grant AssessorAustralian Research Council (ARC) |
2012 |
Ad-Hoc Grant AssessorDFG |
2012 |
Ad-Hoc Grant AssessorRoyal Children Hospital Foundation |
2012 |
Invited presentation2nd Ovarian Cancer Symposium, Singapore |
2012 |
Invited presentationCanadian Proteomics Society meeting |
2012 |
Invited presentationOURCON I, Ourense, Spain |
2012 |
SA representativeAustralasian Peptide Association |
2012 |
Vice PresidentAustralasian Proteomics Society |
2012 |
Vice President and Conference ChairLorne Proteomics Symposium |
2012 |
Ad-Hoc Grant AssessorNational Health and Medical Research Council (NHMRC) |
2011 |
Ad-Hoc Grant AssessorAustralian Cancer Research Foundation |
2011 |
Ad-Hoc Grant AssessorAustralian Research Council (ARC) |
2011 |
Ad-Hoc Grant AssessorDFG |
2011 |
Ad-Hoc Grant AssessorRoyal Children Hospital Foundation |
2011 |
Invited presentationProteomics Forum, Berlin, Germany |
2011 |
SA representativeAustralasian Peptide Association |
2011 |
Session ChairAustralian Peptide Conference |
2011 |
Session ChairLorne Proteomics Symposium |
2011 |
Ad-Hoc Grant AssessorNational Health and Medical Research Council (NHMRC) |
2010 |
Ad-Hoc Grant AssessorAustralian Cancer Research Foundation |
2010 |
Ad-Hoc Grant AssessorAustralian Research Council (ARC) |
2010 |
Ad-Hoc Grant AssessorDFG |
2010 |
Ad-Hoc Grant AssessorRoyal Children Hospital Foundation |
2010 |
Invited presentationHUPO, Sydney, Australia |
2010 |
SA representativeAustralasian Peptide Association |
2010 |
Session ChairAustralian Peptide Conference |
2010 |
Session ChairLorne Proteomics Symposium |
2010 |
Ad-Hoc Grant AssessorNational Health and Medical Research Council (NHMRC) |
2009 |
Ad-Hoc Grant AssessorAustralian Cancer Research Foundation |
2009 |
Ad-Hoc Grant AssessorAustralian Research Council (ARC) |
2009 |
Ad-Hoc Grant AssessorDFG |
2009 |
Ad-Hoc Grant AssessorRoyal Children Hospital Foundation |
2009 |
Biochemistry Project Grant Review Panel MemberNational Health and Medical Research Council (NHMRC) |
2009 |
Directors InitiativeBio Innovation SA |
2009 |
SA representativeAustralasian Peptide Association |
2009 |
Session ChairAustralian Peptide Conference |
2009 |
Session ChairLorne Proteomics Symposium |
2009 |
Ad-Hoc Grant AssessorNational Health and Medical Research Council (NHMRC) |
2008 |
Ad-Hoc Grant AssessorAustralian Cancer Research Foundation |
2008 |
Ad-Hoc Grant AssessorAustralian Research Council (ARC) |
2008 |
Ad-Hoc Grant AssessorDFG |
2008 |
Ad-Hoc Grant AssessorRoyal Children Hospital Foundation |
2008 |
Directors InitiativeBio Innovation SA |
2008 |
SA representativeAustralasian Peptide Association |
2008 |
Session ChairLorne Proteomics Symposium |
2008 |
Teaching & student supervision
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
111153 - Mass Spectrometry assays for protein biomarker for the early detection of ovarian cancer | Current |
Advancing Protein Therapeutic Development | Current |
Developing a DGT methodology to assess bioavailability of herbicide residues | Current |
Examining the 14 3 3 adaptor proteins as a new therapeutic target for childhood medulloblastoma | Current |
Functional Analysis and Quantification of Biopharmaceuticals in Tissues by Mass Spectrometry Imaging | Current |
Linking the intracellular journey of gold nanoparticles to protein expression changes in prostate cancer cells | Current |
Low-temperature plasma jet delivery of reactive species for biomedical applications | Current |
Mass spectrometry and spectroscopic analytical approaches for directed monoclonal antibody formulation development | Current |
Maximising yeast health during the industrial beer brewing process: a proteomics investigation | Current |
Molecular diagnosis for point-of-care skin cancer testing | Current |
PAT Spectroscopic and MS techniques fornear/real-time product characterisation for plasma derived products | Current |
Towards understanding the underlying biological mechanisms ofplasma in medicine | Current |
Tissue-specific N-glycan alterations in human knee osteoarthritis discovered by MALDI mass spectrometry imaging | Completed |
Using high throughput screening to design cell therapy scaffolds | Completed |